↓ Skip to main content

Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations

Overview of attention for article published in Drugs & Aging, July 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (80th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
13 X users

Citations

dimensions_citation
29 Dimensions

Readers on

mendeley
94 Mendeley
Title
Managing Urinary Incontinence in Patients with Dementia: Pharmacological Treatment Options and Considerations
Published in
Drugs & Aging, July 2015
DOI 10.1007/s40266-015-0281-x
Pubmed ID
Authors

Susie Orme, Vikky Morris, William Gibson, Adrian Wagg

Abstract

Urinary incontinence and lower urinary tract symptoms are highly prevalent in late life and are strongly associated with dementia and frailty. Incontinence is extremely common among those living in long-term care and is most commonly due to urgency incontinence. Although national and international guidelines for continence care exist, they often fail to consider the complex comorbidity found in patients with dementia and are often not followed; continence practices in long-term care may promote rather than prevent incontinence. The majority of those with dementia living in the community can be managed successfully with standard treatments, both pharmacological and non-pharmacological; the expectations and aims of treatment of both the patient and their caregivers should be considered. A dementia diagnosis does not preclude management of incontinence, but treatment options may be more limited in those with advanced dementia who are unable to retain information and modify behaviors. High-quality data to guide the choice of pharmacological agent in those with dementia are lacking. Oxybutynin has been shown to have significant adverse cognitive effects, but data to support the use of trospium, solifenacin, darifenacin, and fesoterodine are limited. No data are available for mirabegron. Neither age, frailty, nor dementia should be considered a barrier to pharmacological management, but consideration should be given to the total anticholinergic load. Evidence to guide the treatment of incontinence in this vulnerable patient group is scarce, and available guidelines adapted for each individual's situation should be applied.

X Demographics

X Demographics

The data shown below were collected from the profiles of 13 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 94 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
United States 1 1%
Unknown 92 98%

Demographic breakdown

Readers by professional status Count As %
Other 13 14%
Researcher 10 11%
Student > Ph. D. Student 8 9%
Student > Master 8 9%
Student > Postgraduate 7 7%
Other 18 19%
Unknown 30 32%
Readers by discipline Count As %
Medicine and Dentistry 21 22%
Nursing and Health Professions 9 10%
Pharmacology, Toxicology and Pharmaceutical Science 8 9%
Psychology 8 9%
Social Sciences 6 6%
Other 8 9%
Unknown 34 36%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 June 2021.
All research outputs
#4,343,659
of 23,975,976 outputs
Outputs from Drugs & Aging
#281
of 1,262 outputs
Outputs of similar age
#52,388
of 266,073 outputs
Outputs of similar age from Drugs & Aging
#5
of 19 outputs
Altmetric has tracked 23,975,976 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,262 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has done well, scoring higher than 77% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,073 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 80% of its contemporaries.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.